FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and applies to a method for measuring reactivity of coagulation factor VIII, wherein the method includes a stage wherein (1) a sample produced from blood, containing a substance exhibiting activity relative to functional replacement of coagulation factor VIII, wherein the substance is a bispecific antibody binding with coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated blood coagulation factor X, is brought into contact with (2) one or several substances neutralising a substance exhibiting activity relative to functional replacement of coagulation factor VIII, wherein one or more neutralising substances constitutes one or several substances selected from the group consisting of peptides, polypeptides, organic compounds, aptamers and antibodies neutralising a substance exhibiting activity relative to functional replacement of coagulation factor VIII; followed by measuring reactivity of the coagulation factor by measuring activity of coagulation factor VIII or a coagulation factor VIII inhibitor titre. The group of inventions also relates to a set containing antibodies for use in the described method; an application of the described method for diagnosing the severity of a hemorrhagic disease in an individual.
EFFECT: group of inventions ensures accurate estimation of activity of FVIII in the plasma of a patient with hemophilia A using an APTT-based one-stage coagulation assay and, additionally, accurate estimation of the FVIII inhibitor titre in the plasma of a patient with hemophilia A with an FVIII inhibitor, using an APTT-based Bethesda assay.
16 cl, 4 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY WHICH IS CAPABLE OF NEUTRALIZING A SUBSTANCE HAVING AN ACTIVITY OF AN ALTERNATIVE COAGULATION FACTOR FUNCTION VIII (FVIII) | 2015 |
|
RU2737145C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| BISPECIFIC ANTIBODY HAVING HIGH ACTIVITY, ALTERNATIVE FUNCTION OF COFACTOR FVIII | 2017 |
|
RU2821642C2 |
| ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
| ANTIBODY CONTAINING PREPARATION | 2017 |
|
RU2748046C2 |
| PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII | 2015 |
|
RU2721910C2 |
| METHODS FOR USE OF BISPECIFIC ANTIBODY THAT RECOGNIZES CLOTTING FACTOR IX AND/OR ACTIVATED CLOTTING FACTOR IX AND CLOTTING FACTOR X AND/OR ACTIVATED CLOTTING FACTOR X | 2017 |
|
RU2766233C2 |
| VERSIONS AND ISOFORMS OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY | 2018 |
|
RU2813990C2 |
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
